PPD completes Evidera acquisition, committed to seamless integration

By Melissa Fassbender contact

- Last updated on GMT

Evidera’s real world research services will further strengthen PPD’s peri- and post-approval capabilities. (Image: iStock/Nastco)
Evidera’s real world research services will further strengthen PPD’s peri- and post-approval capabilities. (Image: iStock/Nastco)

Related tags: Subsidiary

Pharmaceutical Product Development, LLC (PPD), has announced the completed acquisition of Evidera as the two companies commit to making the “seamless offering a reality.”

As Outsourcing-Pharma.com previously reported, the contract research organization (CRO) announced the acquisition​ in August of this year, citing the growing need for real-world data.

Jon Williams, president of Evidera, told us the closing the acquisition went smoothly, taking less than four weeks from signing.

We’re aligning the PPD and Evidera teams to uncover opportunities to more effectively generate, interpret and communicate real-world evidence on behalf of our clients​,” he added.

Together, Williams said PPD and Evidera will deliver “comprehensive development strategies​” that will help its clients earn regulatory approval and generate the real-world evidence needed for pricing and reimbursement discussions, as well as for optimized market access. 

Over the coming weeks and months we will create the necessary points of connection and operational processes to make this seamless offering a reality​,” Williams explained.

Evidera will operate as a wholly owned subsidiary of PPD, though Williams said the newly combined company will maintain Evidera’s culture and focus on scientific excellence and thought leadership in real-world research, “while also working very closely with our new parent company​,” he explained.

We expect that PPD’s world-class global operations and regulatory expertise combined with our unparalleled capabilities in the late phase and market access space will not only be a unique asset, but will serve as a unifying force that will bring the two companies together to offer a powerful set of solutions​,” added Williams.

Above all, we are committed to achieving a seamless integration with no loss of focus on innovation, industry leadership and client service​.”

Related news

Show more

Related products

show more

Paper vs ePRO Data Collection Methods

Paper vs ePRO Data Collection Methods

Signant Health | 19-Oct-2021 | Technical / White Paper

Are you curious why more Sponsors choose digital data collection methods over the traditional pen and paper? Read this recent white paper to discover the...

GLP Tissue Cross Reactivity Testing

GLP Tissue Cross Reactivity Testing

Precision for Medicine | 11-Oct-2021 | Product Brochure

Precision for Medicine's unique combination of research services and tissue procurement capabilities form the pillars of our GLP Tissue Cross Reactivity...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Related suppliers

Follow us

Products

View more

Webinars